This US-based key opinion leader (KOL) opines on the treatment strategies employed in targeting wet AMD. The KOL talks about the market splits and drug uptake in patients with wet AMD while also discussing factors pertaining to compliance in patients. He also adds on the impact of Eylea HD, Susvimo and the potential launch of Lytenava on marketed therapies. The KOL also talks on promising pipeline therapies with special interest in gene therapy and also discusses cost of treatments.

This interview was conducted on February 20, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.